Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
L-163,491
Другие языки:

    L-163,491

    Подписчиков: 0, рейтинг: 0
    L-163,491
    L-163491 structure.png
    Legal status
    Legal status
    • US: Investigational drug
    Identifiers
    • Butyl (4'-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-5-(3-methoxybenzyl)-[1,1'-biphenyl]-2-yl)sulfonylcarbamate
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    Chemical and physical data
    Formula C36H40N4O5S
    Molar mass 640.8 g·mol−1
    3D model (JSmol)
    • CCCCOC(=O)NS(=O)(=O)C1=C(C=C(C=C1)CC2=CC(=CC=C2)OC)C3=CC=C(C=C3)CN4C(=NC5=C4N=C(C=C5C)C)CC
    • InChI=1S/C36H40N4O5S/c1-6-8-18-45-36(41)39-46(42,43)32-17-14-28(20-27-10-9-11-30(21-27)44-5)22-31(32)29-15-12-26(13-16-29)23-40-33(7-2)38-34-24(3)19-25(4)37-35(34)40/h9-17,19,21-22H,6-8,18,20,23H2,1-5H3,(H,39,41)
    • Key:SRCIRAKBWHTYIX-UHFFFAOYSA-N

    L-163,491 is an experimental drug which acts as a partial agonist of angiotensin II receptor type 1, and with lower affinity as an agonist of angiotensin II receptor type 2, mimicking the action of angiotensin II. Its practical applications to date have been limited to scientific research into the function of the angiotensin receptor system, but it has been suggested as a potential therapeutic agent for the treatment of inflammation of the lungs associated with certain viral diseases such as COVID-19.



    Новое сообщение